|
| 36806911 | Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. | Clin Cancer Res | 2023 |
| 37289450 | Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review. | JAMA Oncol | 2023 |
| 36719493 | Diagnostic performance of computed tomography features in detecting oropharyngeal squamous cell carcinoma extranodal extension. | Eur Radiol | 2023 |
| 37087370 | Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. | Lancet Digit Health | 2023 |
| 37022706 | Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 37392723 | Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care? | Cancer Treat Rev | 2023 |
| 36945519 | Fully-automated sarcopenia assessment in head and neck cancer: development and external validation of a deep learning pipeline. | medRxiv | 2023 |
| 36806911 | Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. | Clin Cancer Res | 2023 |
| 36479637 | Biomarkers predictive of response to pembrolizumab in head and neck cancer. | Cancer Med | 2023 |
| 36473143 | Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. | J Clin Oncol | 2023 |
| 37392723 | Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care? | Cancer Treat Rev | 2023 |
| 37087370 | Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. | Lancet Digit Health | 2023 |
| 37022706 | Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 37289450 | Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review. | JAMA Oncol | 2023 |
| 36945519 | Fully-automated sarcopenia assessment in head and neck cancer: development and external validation of a deep learning pipeline. | medRxiv | 2023 |
| 36479637 | Biomarkers predictive of response to pembrolizumab in head and neck cancer. | Cancer Med | 2023 |
| 36719493 | Diagnostic performance of computed tomography features in detecting oropharyngeal squamous cell carcinoma extranodal extension. | Eur Radiol | 2023 |
| 36473143 | Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. | J Clin Oncol | 2023 |
| 34665873 | Exposed bone in patients with head and neck cancer treated with radiation therapy: An analysis of the Observational Study of Dental Outcomes in Head and Neck Cancer Patients (OraRad). | Cancer | 2022 |
| 35715285 | Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study. | Ann Oncol | 2022 |
| 35658994 | Head and neck cancer: high-end technology is no guarantee of high-quality care - Authors' reply. | Lancet | 2022 |
| 36179682 | Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. | Cancer Cell | 2022 |
| 36301568 | Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer. | JAMA Otolaryngol Head Neck Surg | 2022 |
| 35641218 | Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. | Oncologist | 2022 |
| 35948029 | Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 35753157 | Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review. | Cancer Treat Rev | 2022 |
| 35803260 | Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. | Cell | 2022 |
| 35355358 | Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. | Head Neck | 2022 |
| 36875716 | Correction: Comprehensive Immunoprofiling of High-risk Oral Proliferative and Localized Leukoplakia. | Cancer Res Commun | 2022 |
| 35050348 | Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. | JAMA Otolaryngol Head Neck Surg | 2022 |
| 34927307 | Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes. | Head Neck | 2022 |
| 35276673 | NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. | J Natl Compr Canc Netw | 2022 |
| 35217573 | Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. | J Immunother Cancer | 2022 |
| 34667025 | Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. | Clin Cancer Res | 2022 |
| 34665873 | Exposed bone in patients with head and neck cancer treated with radiation therapy: An analysis of the Observational Study of Dental Outcomes in Head and Neck Cancer Patients (OraRad). | Cancer | 2022 |
| 35058328 | Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. | J Immunother Cancer | 2022 |
| 35803260 | Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. | Cell | 2022 |
| 35641218 | Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. | Oncologist | 2022 |
| 35753157 | Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review. | Cancer Treat Rev | 2022 |
| 35658994 | Head and neck cancer: high-end technology is no guarantee of high-quality care - Authors' reply. | Lancet | 2022 |
| 35715285 | Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study. | Ann Oncol | 2022 |
| 35355358 | Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. | Head Neck | 2022 |
| 36875716 | Correction: Comprehensive Immunoprofiling of High-risk Oral Proliferative and Localized Leukoplakia. | Cancer Res Commun | 2022 |
| 36179682 | Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. | Cancer Cell | 2022 |
| 36301568 | Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer. | JAMA Otolaryngol Head Neck Surg | 2022 |
| 35948029 | Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 35217573 | Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. | J Immunother Cancer | 2022 |
| 35276673 | NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. | J Natl Compr Canc Netw | 2022 |
| 35058328 | Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. | J Immunother Cancer | 2022 |
| 35050348 | Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. | JAMA Otolaryngol Head Neck Surg | 2022 |